Idera officially puts to rest its Phase III trial in advanced melanoma; BeiGene nabs priority review for sNDA
Idera dropped some disappointing news in late March, when it showed its lead drug failed to hit its primary endpoint in a Phase III …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
